Cancer immunotherapy in the form of immune checkpoint inhibitors has led to a dramatic increase in the survival of patients with lung cancer across all stages. Over the past decade, the field has experienced rapid maturation; however, several challenges continue to complicate patie...
Focusing on gastrointestinal cancer, the synergy of HANSIZHUANG with in-house products of the company and innovative therapies are being actively promoted. This includes extensive clinical development in high-incidence cancers such as colorectal cancer, gastric cancer, liver cancer, and esophageal cancer....
Immunotherapy for cancer has undergone a rapid expansion in classes, agents, and indications. By utilizing aspects of the body’s innate immune system, immunotherapy has improved life expectancy and quality of life for patients with several types of cancer. Adoptive cellular therapies, including chimer...
Lung cancer is one of the malignant tumors with the fastest increasing morbidity and mortality in the world.Although surgical techniques have been improved... QH Li,ZZ Liu - 《Tmr肿瘤进展》 被引量: 0发表: 2022年 review article cancer immunotherapy: priming the host immune response with live ...
Dendritic cells have far-reaching and important effects on the activation of the immune response; thus, they are used to vaccinate patients with cancer to induce long-term anti-tumour immunity. This Review discusses what we know — and need to know — ab
. Although notable progress has been made on novel cancer treatments, the overall survival rate and therapeutic effects are still unsatisfactory for cancer
Immunotherapy as a Promising Treatment for Prostate Cancer: A Systematic Review Janiczek, M.; Szylberg, L.; Kasperska, A.; Kowalewski, A.; Parol, M.; Antosik, P.; Radecka, B.; Marszałek, A. Immunotherapy as a Promising Treatment for Prostate Cancer: A Systematic Review. J. Immunol...
This review will present the main biologic features of Dexo and Texo as cell-free cancer vaccines with emphasis on their immunostimulatory properties and their potential efficacy in cancer immunotherapy. 展开 DOI: 10.1089/cbr.2007.368-R 被引量: 127 ...
W. et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363, 411–422 (2010). CAS PubMed Google Scholar Graff, J. N. & Chamberlain, E. D. Sipuleucel-T in the treatment of prostate cancer: an evidence-based review of its place in therapy. ...
Immunotherapies have emerged as one of the most promising approaches to treat patients with cancer. Recently, there have been many clinical successes using checkpoint receptor blockade, including T cell inhibitory receptors such as cytotoxic T-lymphocyte